The FDA has approved a new drug that promises a simpler and far more effective treatment for drug-resistant tuberculosis. But not everyone is celebrating. Doctors Without Borders has concerns about a critical bottom-line issue: How much will the drug cost in poor and middle-income countries, where most TB patients reside?
Trending:
New drug could be game changer for drug-resistant TB. But a question looms